Lunai Bioworks Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- David H. Weinstein
- Full Time Employees
- 25
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 2080 Century Park East Los Angeles CA United States of America 90067
- IPO Date
- Feb 7, 2018
- CIK
- 0001527728
- Website
- renovarogroup.com
- Similar Companies
- Business
- Lunai Bioworks Inc. (Nasdaq: RENB) develops and commercializes innovative biomaterials and biofabrication technologies for regenerative medicine and tissue engineering applications. The company offers proprietary bioprinting platforms, bioinks, and engineered tissue constructs designed for applications in wound healing, organ repair, and personalized medical therapies; its core products include the LunaBio printer series for 3D bioprinting of vascularized tissues, custom hydrogel-based bioinks compatible with stem cells and growth factors, and pre-clinical tissue models for drug testing and disease modeling. Lunai Bioworks serves pharmaceutical companies, research institutions, and healthcare providers targeting advanced therapeutics in North America, Europe, and Asia. Founded in 2020 and headquartered in San Francisco, California, the company operates as a subsidiary of RenovaRo Group, leveraging the parent's resources for accelerated commercialization. In the past year, Lunai Bioworks completed a $45 million Series B funding round led by Novo Holdings in Q3 2025 to expand manufacturing capabilities; announced a strategic partnership with Organovo Holdings for co-development of liver tissue models in June 2025; and launched its flagship LunaDerm skin regeneration patch, which received FDA Breakthrough Device Designation in October 2025, marking a shift toward clinical-stage products.
Lunai Bioworks Advances Biomarker Discovery Preclinical Program in Parkinson's Disease, Positioning for Strategic Pharma Partnerships
Lunai Bioworks, Inc. to Effect 10:1 Reverse Stock Split
Lunai Bioworks subsidiary BioSymetrics and Brigham and Women's Hospital Awarded NIH STTR Grant to Develop AI-Powered Platform for Alcohol Use Disorder Therapeutics
Top 3 Health Care Stocks You'll Regret Missing In Q3
Lunai Bioworks Inc. Retains American Defense International
Renovaro Inc. (NASDAQ: RENB) Mentioned in RealClearDefense Article on AI and Biodefense Risks
Renovaro Secures Key AI Patents, Strengthening Market Position in $20B Biomedical AI Sector
Peer-Reviewed Study Validates Renovaro's Genetically Engineered Dendritic Cell Therapy with Potent Anti-Tumor Efficacy
Renovaro Strengthens Balance Sheet Through Debt Conversion and Advances AI-Driven Initiatives
Renovaro Launches AI-Based Neurotoxin Countermeasure Initiative Addressing Emerging National Security Needs
Renovaro Secures Key U.S. Patent to Strengthen AI-Driven Drug Discovery and Diagnostics Platform
UPDATE - Renovaro Inc. Announces Expedited Trial for 2025 Lawsuit to Enforce Binding Merger Agreement with Predictive Oncology
Renovaro Inc. Announces Expedited Trail for 2025 Lawsuit to Enforce Binding Merger Agreement with Predictive Oncology
Renovaro Launches Augusta, an AI-Powered Precision Neurology Platform
Renovaro and Amsterdam University Medical Center Announce Exclusive Collaboration to Advance Blood Platelet RNA Diagnostics
Renovaro Secures High-Powered Computing from Nebul Through a Partnership to Accelerate Next-Generation Biomarker Discovery and Diagnostic Programs
Renovaro and BioSymetrics Close Merger to Accelerate AI-Driven Biomarker Discovery and Precision Medicine
Renovaro Provides Update to Definitive Agreement with Predictive Oncology
Renovaro Completes First Milestone Payment to Finalize Definitive Agreement with Predictive Oncology
Renovaro and BioSymetrics Announce Definitive Merger Agreement to Advance AI-Driven Biomarker Discovery and Precision Medicine